​

Trevi Therapeutics Ownership | Who Owns Trevi Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Trevi Therapeutics Ownership Summary

Trevi Therapeutics is owned by 97.56% institutional investors, 0.68% insiders, and 1.76% retail investors. Nea management company is the largest institutional shareholder, holding 10.14% of TRVI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.56% of its assets in Trevi Therapeutics shares.

TRVI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTrevi Therapeutics97.56%0.68%1.76%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company13.22M10.14%$120.98M
Frazier life sciences management10.26M7.87%$93.87M
Blackrock funding, inc. /de9.90M7.60%$90.59M
Rubric capital management lp8.53M6.55%$78.07M
Vanguard group5.83M4.47%$53.32M
Viking global investors lp5.13M3.93%$46.93M
Vivo capital5.09M3.91%$46.62M
Marshall wace, llp4.84M3.71%$44.30M
Morgan stanley4.30M3.30%$39.36M
Alliancebernstein4.29M3.29%$39.28M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acorn capital advisors2.14M9.96%$19.63M
Pivotal bioventure partners investment advisor1.26M6.65%$11.50M
Nea management company13.22M6.64%$120.98M
Bioimpact capital3.41M5.10%$31.17M
Octagon capital advisors lp2.81M3.90%$25.76M
Vivo capital5.09M3.75%$46.62M
Artia global partners lp2.00M2.90%$18.30M
Frazier life sciences management10.26M2.81%$93.87M
Affinity asset advisors2.80M2.23%$25.62M
Logos global management lp2.20M1.80%$20.13M

Top Buyers

HolderShares% AssetsChange
Viking global investors lp5.13M0.12%3.59M
Morgan stanley4.30M0.00%3.28M
Wellington management group llp3.25M0.01%3.08M
Fmr3.30M0.00%2.93M
Marshall wace, llp4.84M0.04%2.36M

Top Sellers

HolderShares% AssetsChange
Woodline partners lp100.28K0.00%-3.95M
Armistice capital---2.99M
Siren2.54M0.91%-1.40M
Checkpoint capital---1.08M
Octagon capital advisors lp2.81M3.90%-857.00K

New Positions

HolderShares% AssetsChangeValue
Peregrine capital management620.46K0.17%620.46K$5.68M
Stempoint capital lp350.71K0.64%350.71K$3.21M
Velan capital investment management lp205.00K1.76%205.00K$1.88M
Swiss national bank161.70K0.00%161.70K$1.48M
Ubs asset management americas116.48K0.00%116.48K$1.07M

Sold Out

HolderChange
Eversource wealth advisors-1.00
Twin peaks wealth advisors-2.00
Nelson, van denburg & campbell wealth management group-6.00
Allworth financial lp-20.00
Rothschild investment-40.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251699.03%127,167,79618.08%971.43%99-1.98%4334.38%
Jun 30, 202516214.08%114,632,70430.70%871.58%1046.12%336.45%
Mar 31, 202514224.56%88,122,13510.86%741.21%9836.11%3233.33%
Dec 31, 202410710.31%67,554,27516.23%662.02%6634.69%2531.58%
Sep 30, 20249725.97%58,119,8883.96%571.82%4913.95%1926.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.12M2.56%-69.28K
Vanguard US Total Market Shares ETF1.78M1.84%-
Fidelity Select Biotechnology2.16M1.77%1.80M
AB Small Cap Growth A2.09M1.72%119.29K
iShares Russell 2000 ETF1.83M1.51%-
Eventide Healthcare & Life Sciences I1.38M1.13%1.38M
BlackRock Advantage Small Cap Core Instl844.90K0.69%-
Vanguard Institutional Extnd Mkt Idx Tr793.99K0.65%-365.90K
Fidelity Small Cap Index761.49K0.63%5.37K
iShares Russell 2000 Growth ETF660.91K0.54%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 25, 2025SCIASCIA THOMAS Chief Scientific OfficerSell$17.36K
Mar 21, 2025GOOD JENNIFER L President & CEOSell$34.62K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$31.10K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$517.78K
Sep 06, 2024GOOD JENNIFER L President & CEOSell$12.78K

Insider Transactions Trends

DateBuySell
2025 Q4--
2025 Q2--
2025 Q1-4
2024 Q4--
2024 Q3-10

TRVI Ownership FAQ

Who Owns Trevi Therapeutics?

Trevi Therapeutics shareholders are primarily institutional investors at 97.56%, followed by 0.68% insiders and 1.76% retail investors. The average institutional ownership in Trevi Therapeutics's industry, Biotech Stocks , is 45.22%, which Trevi Therapeutics exceeds.

Who owns the most shares of Trevi Therapeutics?

Trevi Therapeutics’s largest shareholders are Nea management company (13.22M shares, 10.14%), Frazier life sciences management (10.26M shares, 7.87%), and Blackrock funding, inc. /de (9.9M shares, 7.60%). Together, they hold 25.61% of Trevi Therapeutics’s total shares outstanding.

Does Blackrock own Trevi Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Trevi Therapeutics.

Who is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested?

Acorn capital advisors is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.96% of its assets in 2.14M Trevi Therapeutics shares, valued at 19.63M$.

Who is the top mutual fund holder of Trevi Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Trevi Therapeutics shares, with 2.56% of its total shares outstanding invested in 3.12M Trevi Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools